Fulvicin
Fulvicin Price range: $ 25,00 through $ 160,00
Back to products
Furosemide
Furosemide Price range: $ 46,00 through $ 193,00

Furazolidone

Price range: $ 6,00 through $ 27,00

Furazolidone is a potent antibacterial and antiprotozoal agent designed to treat a variety of intestinal infections. This medication is specifically indicated for the management of giardiasis, cholera, and bacterial diarrhea caused by susceptible pathogens. By disrupting essential microbial enzyme systems, it effectively stops the growth and spread of harmful organisms within the digestive tract. It provides a targeted approach to gastrointestinal relief, helping to eliminate the underlying cause of infection. Its reliable efficacy makes it a standard option for addressing specific enteric conditions and supporting overall digestive health.

Active substance: Furazolidone
SKU: Furazolidone Categories: ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Furazolidone belongs to the nitrofuran class of synthetic antimicrobial agents, exhibiting both antibacterial and antiprotozoal activity. Historically developed to target gastrointestinal pathogens, this substance interferes with vital microbial enzymatic processes to control specific intestinal infections. Any distribution or clinical use must be dispensed in accordance with applicable federal and state regulations.

Because furazolidone exhibits monoamine oxidase (MAO) inhibiting activity, its pharmacological profile requires careful oversight regarding dietary intake and concurrent drug administration. Patients should understand that antibacterial agents are specific to susceptible microbial strains and are ineffective against viral conditions such as the common cold or influenza.

Property Specification
Drug name Furazolidone
Active ingredient Furazolidone
Therapeutic class Nitrofuran antimicrobial / Antiprotozoal agent
Dosage form Oral tablet, oral suspension
Route of administration Oral
Prescription status Dispensed in accordance with applicable federal and state regulations

Overview and Clinical Profile

Main Uses and Mechanism of Action

Main uses

Furazolidone is indicated for the treatment of bacterial enteritis and diarrheal illness caused by susceptible organisms, as well as protozoal infections such as giardiasis caused by Giardia lamblia. It has demonstrated clinical utility against specific gastrointestinal pathogens including Vibrio cholerae, Salmonella species, Shigella species, and enterotoxigenic Escherichia coli. Healthcare providers evaluate microbial susceptibility prior to initiating therapy, as efficacy is limited strictly to susceptible bacterial and protozoal isolates. Any application outside established microbial coverage is considered off-label and requires specific diagnostic justification by a licensed clinician.

How the drug works

The antimicrobial activity of furazolidone relies on its enzymatic reduction within microbial cells. Bacterial nitroreductase enzymes convert the parent nitrofuran compound into reactive metabolic intermediates. These active metabolites induce oxidative stress, cause breakages in bacterial deoxyribonucleic acid (DNA), and disrupt essential ribosomal protein synthesis. In addition to its antimicrobial actions, furazolidone exhibits significant monoamine oxidase (MAO) inhibitory activity in human tissue. This secondary pharmacologic effect slows the catabolism of catecholamines and exogenous amines, which accounts for key dietary and drug interaction profiles associated with the agent.

Safety Profile and Drug Interactions

How it’s absorbed and eliminated

Following oral administration, furazolidone remains predominantly active within the lumen of the gastrointestinal tract, which supports its therapeutic targeted effect against enteric pathogens. A portion of the dose is absorbed systemically and undergoes extensive biotransformation in body tissues. Metabolism occurs rapidly, breaking the nitrofuran ring into multiple inactive metabolites. Excretion occurs primarily through the kidneys, with metabolites eliminated in the urine. This renal elimination pathway frequently causes a harmless, temporary brown or dark-yellow discoloration of the urine during active treatment cycles.

Dosing schedule

The dosage and duration of furazolidone therapy are determined individually by a licensed healthcare provider based on the patient’s age, body weight, renal function, and the specific underlying pathogen. Oral formulations are typically administered at regular intervals throughout the day to maintain effective luminal concentrations. Patients must complete the full prescribed course of therapy even if symptoms improve early. Abruptly terminating treatment may lead to incomplete microbial eradication and increase the potential for bacterial resistance. Dosage adjustments are mandatory in pediatric populations according to clinical guidelines.

Compatibility with other medicines

Due to its action as a monoamine oxidase inhibitor (MAOI), furazolidone carries extensive drug interaction potential. Co-administration with sympathomimetic agents, such as phenylephrine, pseudoephedrine, or amphetamines, can provoke a rapid and dangerous surge in blood pressure. Concurrent use with selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, or meperidine is contraindicated due to the severe risk of serotonin syndrome or hypertensive crisis. Furthermore, combining furazolidone with other blood dyscrasia-inducing medications or monoamine-altering substances requires extreme caution and clinical monitoring.

Food and alcohol interactions

Ingestion of alcohol during furazolidone therapy or within four days after completing the medication course can trigger a disulfiram-like reaction. This severe interaction manifests as facial flushing, throbbing headache, dyspnea, sweating, tachycardia, and a precipitous drop in blood pressure. Additionally, patients must avoid foods rich in tyramine, such as aged cheeses, cured meats, broad beans, yeast extracts, and fermented beverages. Tyramine ingestion during MAO inhibition can precipitate a hypertensive crisis characterized by severe headache, visual disturbances, and cardiovascular distress.

Adverse reactions

The administration of furazolidone may elicit several untoward effects across different organ systems. Gastrointestinal adverse effects are common and include nausea, vomiting, abdominal cramps, diarrhea, and anorexia. Neurological symptoms such as headache, dizziness, and malaise have also been reported. Hypersensitivity reactions may manifest as fever, skin rash, joint pain, or urticaria. Hematologic adverse reactions represent a significant clinical concern; the drug can induce intravascular hemolysis, particularly in individuals with underlying glucose-6-phosphate dehydrogenase (G6PD) deficiency. Granulocytopenia and orthostatic hypotension may also occur.

Important precautions

Furazolidone is contraindicated in patients with known hypersensitivity to nitrofuran compounds. It must not be administered to infants under one month of age due to the instability of their enzyme systems and the heightened risk of hemolytic anemia. Individuals with G6PD deficiency should not receive this drug because of the substantial risk of acute hemolytic reactions. Pre-clinical long-term toxicology studies in rodent models have demonstrated tumorigenic potential, necessitating that human use be confined strictly to established, evidence-based indications under professional medical supervision. Pregnant and lactating individuals should avoid use unless explicitly directed by a prescriber.

Red flags

Patients taking furazolidone should be aware of critical clinical signals that necessitate urgent medical evaluation. Immediate emergency care is required if signs of severe systemic allergy emerge, such as swelling of the face, lips, tongue, or throat, alongside severe difficulty breathing or diffuse blistering skin lesions. Sudden, severe headache, severe chest discomfort, or rapid, irregular heartbeat may signal an acute hypertensive episode linked to MAO inhibition. Development of marked pallor, extreme fatigue, dark tea-colored urine, or jaundice indicates potential acute hemolysis and warrants immediate cessation of therapy and emergency intervention.

If you skip a dose

If a dose of furazolidone is missed, it should be taken as soon as remembered, provided the next scheduled dose is not imminent. If the time is close to the next scheduled administration, the missed dose should be skipped entirely, and the regular dosing interval resumed. Patients must never double a dose or take extra medicine to compensate for a skipped administration, as elevated serum and luminal concentrations increase the frequency and severity of toxic reactions.

Storage and expiration

Furazolidone preparations should be stored at controlled room temperature, away from excessive light, heat, and moisture. Store oral suspensions and tablets in tightly closed, light-resistant containers. Keep all pharmaceutical products out of the reach of children and pets. Do not use any medication beyond the printed expiration date on the package. Expired or unused medication should be disposed of via authorized drug take-back programs or in accordance with local environmental regulations.

Frequently Asked Questions

Key Operational Guidance

Why does urine turn dark or brown during furazolidone therapy?

The metabolic breakdown of furazolidone results in water-soluble nitrofuran metabolites that are excreted via the kidneys. These metabolites impart a yellow-brown to dark-brown color to the urine. This discoloration is a harmless, expected pharmacologic effect and does not indicate renal damage or internal bleeding.

Can alcohol be consumed during treatment with furazolidone?

Alcohol consumption is strictly contraindicated during furazolidone therapy and for at least four days after the final dose. Furazolidone inhibits aldehyde dehydrogenase, causing an accumulation of acetaldehyde upon alcohol ingestion. This produces a severe disulfiram-like reaction characterized by nausea, flushing, chest tightness, and rapid heart rate.

Is furazolidone effective for treating viral gastroenteritis or the flu?

Furazolidone possesses activity against susceptible bacteria and specific protozoa; it has no antiviral activity. Taking furazolidone for viral infections such as viral gastroenteritis, influenza, or the common cold is ineffective and exposes the individual to unnecessary drug risks and potential antimicrobial resistance.

Special Population Warnings

What precautions apply to patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency?

Patients with G6PD deficiency are at severe risk of developing drug-induced hemolytic anemia when exposed to nitrofuran derivatives, including furazolidone. The medication causes oxidative stress on red blood cells, leading to premature cell lysis. Screening for enzyme deficiency is recommended prior to administration when risk factors are present.

What dietary restrictions must be followed during furazolidone treatment?

Because furazolidone acts as a monoamine oxidase inhibitor, patients must refrain from consuming foods containing high levels of tyramine. This includes aged cheeses, broad beans, yeast extracts, processed meats, and fermented food items. Ingesting tyramine while taking an MAO inhibitor can trigger dangerous elevations in blood pressure.

This text is for informational purposes only and does not constitute individual medical advice. In accordance with FDA requirements.

Additional information
Dosage

100 mg

Package

30 tabs

,

60 tabs

,

100 tabs

,

200 tabs

Ενεργός Ουσία